---
title: "Chinese Drug Regulator Accepts Aosaikang Pharma Unit's Marketing Application for  Isavuconazole Sulfate Capsules; Shares Down 4%"
date: "2025-02-11 14:10:48"
summary: "China's National Medical Products Administration accepted the marketing application of Beijing Aosaikang Pharmaceutical's unit, Jiangsu Aosaikang Pharmaceutical, for isavuconazole sulfate capsules, according to a Shenzhen Stock Exchange disclosure on Monday. The drug is used to treat adults infected with invasive aspergillosis and invasive mucormycosis, the pharmaceutical company said. The company's..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

China's National Medical Products Administration accepted the marketing application of Beijing Aosaikang Pharmaceutical's unit, Jiangsu Aosaikang Pharmaceutical, for isavuconazole sulfate capsules, according to a Shenzhen Stock Exchange disclosure on Monday.

The drug is used to treat adults infected with invasive aspergillosis and invasive mucormycosis, the pharmaceutical company said.

The company's shares fell less than 4% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466071:0/)
